Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T01822
(Former ID: TTDI01208)
|
|||||
Target Name |
Haematin (HA)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Malaria [ICD-11: 1F40-1F45] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | Ferroquine | Drug Info | Phase 2 | Malaria | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 1 Inhibitor drugs | + | ||||
1 | Ferroquine | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Insights into the mechanism of action of ferroquine. Relationship between physicochemical properties and antiplasmodial activity. Mol Pharm. 2005 May-Jun;2(3):185-93. | |||||
REF 2 | ClinicalTrials.gov (NCT00988507) Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.